Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors
EPIC: GDR
Market: AIM
52-week High/Low: 65.00p / 30.00p
Sector: Pharma & Biotech
Market Cap: 7.01M
Genedrive PLC

Genedrive PLC

The Genedrive® molecular diagnostic system has been developed as an affordable next generation genotyping and sequence analysis device, providing rapid detection in approximately 45-75 minutes depending on the test.
The first test developed on the Genedrive® is MTB/RIF which allows small/medium laboratories to test for TB thus speeding up diagnosis and treatment and improving prognosis.

Genedrive PLC

www.genedrive.com

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Genedrive PLC


Genedrive PLC Snapshot

The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc. With its historical founding in the provision of contract research services to Pharmaceutical and Biotech companies, the business was renamed genedrive plc in July 2016. The name reflects the new direction of the company targeting molecular diagnostic requirements at the point of need, with shareholder expectations being directed at the superior returns offered by the Genedrive® business model.

The company operates under three active Divisions.

Diagnostics

The Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based tests via a 'razor/razor blade' business model across an increasing range of applications. The instrument's development has been significantly de-risked through a range of varied applications and external independent validations.

Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid patient diagnostics.

Pharmacogenomics

The Epistem Pharmacogenomics Division specialises in providing gene expression and DNA genotyping information utilising knowledge developed working with epithelial stem cells and obtaining gene expression information from tiny amounts of starting material. The Pharmacogenomics Division has evolved to capitalise on this proprietary knowledge, providing innovative services and developing pioneering products. The Division provides GCLP accredited gene expression and genotype analysis for drug development and diagnostic programs. The unique combination of in-house expertise and proprietary knowledge ensures that the Division is a preferred partner of choice for pharmaceutical and biotechnology companies worldwide.

Contract Research Services

The Epistem Contract Research Services Division is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline. Underpinned by world-renowned knowledge of epithelial stem cell biology, Contract Research Services provide comprehensive integrated service packages across key therapeutic areas. The Division continues to develop innovative and clinically relevant assays and models, collaborating with commercial partners, participating in grant applications and supporting government initiatives.

Diagnostics
The Genedrive molecular diagnostics division is developing and commercialising its low cost versatile, simple to use and robust point-of-need or point-of-care Genedrive® diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform MTB/RIF test has been launched in India and a Genedrive® HCV test has been successfully assessed by Institute Pasteur, Paris.


Pharmacogenomics
The Company's Pharmacogenomics Division trades as Epistem and specialises in providing gene expression and DNA genotyping information utilising knowledge developed working with epithelial stem cells and obtaining gene expression information from small amounts of starting material. The Pharmacogenomics Division has evolved to capitalise on this proprietary knowledge, providing innovative services and developing pioneering products. The Division provides GCLP accredited gene expression and genotype analysis for drug development and diagnostic programs. The unique combination of in-house expertise and proprietary knowledge ensures Epistem's Personalised Medicine Service is a preferred partner of choice for pharmaceutical and biotechnology companies worldwide.


Contract Research Services
The Company's Contract Research Services Division trade as Epistem and is committed to providing reliable, innovative and transferable pre-clinical models and services to support decision making throughout the drug discovery and development pipeline. Underpinned by world-renowned knowledge of epithelial stem cell biology, Contract Research Services provides comprehensive integrated service packages across key therapeutic areas. The Division continues to develop innovative and clinically relevant assays and models, collaborating with commercial partners, participating in grant applications and supporting government initiatives. The Epistem Contract Research Services Division strives to be a leader in the field of pre-clinical testing.


Novel Therapies
Utilising the Epistem scientific heritage and expertise in epithelial stem cells, the Novel Therapies Division aims to identify key regulators of epithelial stem cell regulators and develop novel therapeutics targeting this mechanism. Following successful industry collaborations, the Epistem Novel Therapies Division retains a portfolio of assets relating to the discovery and development of epithelial stem cell regulators, with implications in both oncology and regenerative medicine.

Ian Gilham - Ph.D., Non-Executive Chairman

Ian was appointed a Director on 24 November 2014 and as Non-Executive Chairman on 11 May 2015. He is currently Non-Executive Chairman of three life sciences companies including AIM-quoted Horizon Discovery Group Plc, which provides gene-editing tools to support translational genomics and the development of personalised medicine, Multiplicom NV focussed on the development and commercialisation of next generation DNA sequencing products and Biosurfit SA, focussed on development and commercialisation of point-of-care diagnostic products. Dr Gilham was formerly Chief Executive Officer of Axis-Shield Plc.

David Budd - Chief Executive Officer

David was appointed a Director and Chief Executive on March 1, 2016. He has over 20 years of international commercial and operational experience in the diagnostics and medical devices field.  He previously served as General Manager of Leica Biosystems Amsterdam and Commercial Director at Leica Biosystems Newcastle, with global responsibility for marketing, product development, and commercial launches for diagnostic tests. Prior to Leica, David’s roles included Point-of-Care, molecular, and central laboratory marketing and commercialisation responsibilities at Siemens Healthcare Diagnostics, Bayer Diagnostics, and Visible Genetics.

Matthew Fowler - Chief Financial Officer

Matthew was appointed Chief Financial Officer on December 13th 2016. He has over 15 years of experience in senior positions in the manufacturing, power and support services industries. Prior to joining genedrive, Matthew spent eight years as Group Financial Controller of Scapa Group plc, a multinational manufacturing AIM-quoted business. At Scapa Group plc, Matthew was responsible for shaping and managing finance within the Group as well as strategy development and other core processes. Prior to that, Matthew spent three years at British Nuclear Group as Finance Manager where he managed the corporate centre's finance team and was responsible for planning, reporting and accounting. Matthew trained and qualified in the audit department of Deloitte & Touche.

Catherine Booth - Ph.D., Managing Director, Contract Research Services

Catherine is a co-founder of Epistem, now genedrive plc, and prior to starting Epistem she worked for 10 years with Prof. Chris Potten at the Paterson Institute. Whilst at the Paterson Institute she developed many preclinical assays. This knowledge is at the core of the Contract Research Service. Catherine received her Ph.D. from the Emmanuel College, University of Cambridge.

Allan Brown - Ph.D., Chief Operating Officer, Diagnostics Division

Allan was appointed to the Board on 1st February, 2014. During a seventeen year period with Tepnel Life Sciences plc, latterly as Divisional Managing Director, Allan's management roles covered product development, commercial product launch, BD and M&A. Allan left Tepnel in 2010 to join Qiagen N.V. in Manchester, and managed the final development and launch of the company's first US FDA approved products, helping secure the site as QIAGEN's Global Centre of Excellence for molecular diagnostic product development.

Roger Lloyd - Ph.D., Non-Executive Director

Trained as a biochemist, Roger has almost 35 years' experience in the healthcare and biotechnology sector, particularly in the areas of strategic planning and business development. International business management with ICI Plc and AstraZeneca Plc. As Executive Director of Global Licensing at AstraZeneca, he personally completed 24 transactions, including strategic alliances with Abgenix and CAT, and acquisitions of KuDOS Pharmaceuticals and CAT. He operates as a Board Adviser in the biotech sector.

Robert Nolan - Ph.D., Non-Executive Director

Robert has been a Non-Executive Director of the Company since 2004. He brings with him a wealth of expertise in partnering and licensing negotiations with both small biotechnology and large pharmaceutical companies. Prior to his retirement he was Director, Global Licensing at AstraZeneca. He is also a non-executive Director of Phico Therapeutics Ltd.

Identity and percentage holding of significant shareholders

  Shares held %
Directors and related shareholders  
Catherine Booth 991,339 5.30%
Hugh John Joseph Rylands 375,076 2.01%
Allan Brown 57,924 0.31%
Ian Gilham 51,750 0.28%
David Budd 31,250 0.17%
Roger Lloyd 12,500 0.07%
Robert Nolan 5,065 0.03%
 
Total Directors' holdings 1,524,895 8.16%
Dr B Cobb 491,228 2.63%
Remaining shares in public hands 16,673,323 89.21%
Total shares in issue 18,689,446 100.00%
 
Substantial holdings  
Calculus Capital 3,031,250 16.22%
Odey Asset Management 2,398,254 12.83%
River and Mercantile Asset Management 1,055,000 5.64%
M&G Investments 853,490 4.57%
Amati Global Investors 781,250 4.18%

 

genedrive plc
48 Grafton Street
Manchester
M13 9XX
UK

Tel: +44 (0)161 989 0245
Fax: +44 (0)161 989 0262

Email: [email protected]

Company Secretary

Matthew Fowler
48 Grafton Street
Manchester M3 9XX

Principal Bankers
Natwest Commercial Banking
5th Floor, 1 Spinningfields Square
Deansgate
Manchester M3 3AP


Nominated Advisor and Broker
Peel Hunt LLP
120 London Wall
London
EC2Y 5ET


Registrars
Neville Registrars Limited
18 Laurel Lane
Halesowen
B63 3DA


Auditors
PricewaterhouseCoopers LLP
101 Barbirolli Square
Lower Mosley Street
Manchester M2 3PW


Legal Advisers
Covington & Burling LLP
265 Strand
London WC2R 1BH


Financial PR and Communications
Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

Genedrive PLC Timeline

Columns Including GDR

VIEW ALL

Market Reports Including GDR

VIEW ALL
Video RSS

Videos

VIEW ALL VIDEOS

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use